Monthly Archives: December 2017

Contentious Tax Reforms Pass Senate

The Republican Party enjoys a majority in both the Senate and the House of Congress and so, theoretically, has a free-hand to pass whatever legislation it wishes. This situation has finally allowed passage of one of President Trump’s flagship policies, a major tax upheaval. Critics of the tax reforms claim that it represents a major…

5 Stocks To Crush The Market In 2018 As EV Race Heats Up

The automotive industry is currently undergoing radical transformation. Strict emission standards and the proposals made by a few Asian and European countries to prohibit internal combustion engines driven by fossil fuels, has prompted a number of traditional automakers across the globe to gear up for electric vehicles (EVs).   The present market share of EVs…

Morning Call For Wednesday, Dec. 20

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps (ESH18 +0.33%) this morning are up +0.30% after the U.S. Senate passed tax reform legislation by a 51-48 vote early this morning. The tax bill now goes back to the House for a second vote in a procedural move before it goes to President Trump to be signed into law….

EC Are Bank Ho

from the St Louis Fed — this post authored by Julie Stackhouse, Executive Vice President Not so very long ago, at the height of the financial crisis, a fall 2008 headline asked, “Why is Everyone Becoming a Bank Holding Company?”[ 1] Not 10 years later, a few mid-sized banking organizations appear to be going the other…

The Gutting Of Household Equity

Funds to sustain Canadian consumer spending over the past several years, have come largely from credit–not income or savings. Thus, consumer debt has driven nearly all of the economy’s growth since 2014 and caused many observers to quite rationally ask, when will Canada hit the end of this debt binge? (Debt to GDP shown here…

Credit Suisse Upgrades Biogen With ‘Significant Turnaround&

Credit Suisse analyst Alethia Young upgraded Biogen (BIIB) to Outperform from Neutral and raised her price target for the shares to $385 from $321. The stock closed yesterday up $1.07 to $327.02. The analyst this morning also downgraded Gilead Sciences (GILD) to Neutral from Outperform. A “significant turnaround” is underway for Biogen’s business, Young tells…